Io Biotech, Inc. (IOBT)

$1.29

-0.05

(-3.73%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.28
    $1.36
    $1.29
    downward going graph

    0.78%

    Downside

    Day's Volatility :5.88%

    Upside

    5.15%

    downward going graph
  • $0.82
    $2.18
    $1.29
    downward going graph

    36.72%

    Downside

    52 Weeks Volatility :62.56%

    Upside

    40.83%

    downward going graph

Returns

PeriodIo Biotech, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-5.63%
6.5%
0.0%
6 Months
-25.14%
7.1%
0.0%
1 Year
-28.34%
9.8%
0.0%
3 Years
-91.44%
14.2%
-20.2%

Highlights

Market Capitalization
88.9M
Book Value
$1.75
Earnings Per Share (EPS)
-1.69
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-44.21%
Return On Equity TTM
-73.85%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-93.5M
Diluted Eps TTM
-1.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.26
EPS Estimate Next Year
-1.34
EPS Estimate Current Quarter
-0.36
EPS Estimate Next Quarter
-0.35

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Io Biotech, Inc.(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
11
11
Hold
2
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 520.16%

Current $1.29
Target $8.00

Technicals Summary

Sell

Neutral

Buy

Io Biotech, Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Io Biotech, Inc.
Io Biotech, Inc.
13.56%
-25.14%
-28.34%
-91.44%
-91.44%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Io Biotech, Inc.
Io Biotech, Inc.
NA
NA
NA
-1.26
-0.74
-0.44
NA
1.75
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Io Biotech, Inc.
Io Biotech, Inc.
Buy
$88.9M
-91.44%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Io Biotech, Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 89.9%

Institutional Holdings

  • Vivo Capital, LLC

    9.37%

  • Novo A/S

    7.72%

  • Samsara BioCapital, LLC

    5.53%

  • Partner Fund Management LP

    3.55%

  • Morgan Stanley - Brokerage Accounts

    3.34%

  • Marshall Wace Asset Management Ltd

    3.20%

Company Information

io biotech is a clinical stage biotech company developing disruptive immune therapies for immunological treatment of cancer. our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of t cells that are specific for immune inhibitory molecules. io biotech has achieved a proven track record of progressing compounds to the clinic, and has two lead immune modulating anti-cancer therapies targeting ido and pd-l1 in clinical development and several compounds finalizing preclinical phase. io biotech has an experienced management team within immuno-oncology fields and a world-class advisory board.

Organization
Io Biotech, Inc.
Employees
70
CEO
Dr. Mai-Britt Zocca Ph.D.
Industry
Services

Discover More

FAQs